A Comparative Analysis of Two Hyaluronic Acid Fillers for Nasolabial Fold Correction
Completed · Not applicable · NCT06351293
Conditions: Wrinkle
At a glance
- Research payments reported, 2025
- $72,400
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 15
About the trial
- Sponsor
- Galderma R&D
- Tested
- Defyne Treatment in Nasolabial Fold (device), RHA3 Treatment in Nasolabial Fold (device)
- Dates
- Started 2024-02-21; completion 2025-04-30
- Results posted
- Not yet
This is a randomized, split-face, subject-blinded, comparative study. Subjects will receive initial treatment with Defyne on one of the NLFs and with RHA3 on the other based on the pre-determined randomization. 4 weeks after the initial treatment, subjects will receive optional touch-up on one side or both sides at the Investigator's discretion for optimal correction. Subjects to return to the site at Month 3, 6, and 12 for follow-ups.
From ClinicalTrials.gov, last updated 2026-01-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Galderma Laboratories, L.P. reported $72,400 in research payments for this study in 2025 (3 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Steven F Weiner MD Consulting LLC $72,400
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.